XYP-001 / Joincare - LARVOL DELTA

Health Yuan: XYP-001 obtained the drug clinical trial approval notice [Google translation] (Shanghai Securities News) - "HealthYuan announced that the company has received the approval of the State Drug Administration to issue the 'Drug Clinical Trial Approval Notice' on XYP-001. XYP-001 is an improved new drug developed by the company. Intended for the treatment of idiopathic pulmonary fibrosis (IPF). This product is a new mechanism/target drug in the field of IPF indication development."

New trial • Idiopathic Pulmonary Fibrosis